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sclerosis associated mutation T109M displays 
unaltered actin binding and does not affect the 
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Abstract 
Background: The recent identification of several mutations in PFN1, a protein involved in actin dynamics, strength‑
ens the hypothesis that pathology of amyotrophic lateral sclerosis is linked to cytoskeletal defects. Impaired actin 
binding is a common denominator of several PFN1 mutations associated with amyotrophic lateral sclerosis, although 
further mechanisms may also contribute to the death of motor neurons. In this study we examine the actin binding 
properties of PFN1 carrying the causal T109M mutation and its effects on the actin cytoskeleton.
Methods: Actin binding of PFN1 T109M was examined by co‑immunoprecipitation experiments, a split luciferase 
complementation assay and a pulldown assay with recombinant PFN1. The actin cytoskeleton was investigated by 
fluorescence microscopy and by ultracentrifuge separation of globular and filamentous actin fractions followed by 
Western blotting.
Results: Using different technical approaches we show that PFN1 T109M displays unaltered actin binding. Further‑
more we show that the actin cytoskeleton is not affected by PFN1 carrying the T109M mutation.
Conclusion: Our data suggest that actin independent mechanisms contribute to the pathogenicity of PFN1 T109M 
and possibly other PFN1 mutations.
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Background
Familial cases of the fatal neurodegenerative disease 
amyotrophic lateral sclerosis (ALS) comprise about 
10  % of all cases. Approximately two-thirds thereof can 
be explained by mutations in known ALS genes, with 
C9orf72, SOD1, TARDBP and FUS being the most fre-
quent [1]. Recently, mutations in several other genes, e.g. 
PFN1 [2] or HNRNPA1 [3], have been shown to be a rare 
cause of ALS. Analysis of these rare causal mutations is a 
valuable tool for the uncovering of altered pathways pos-
sibly common to ALS pathogenesis.
The discovery that PFN1 mutations cause ALS [2] 
implicates disturbed dynamics of the cytoskeleton in 
degeneration of motor neurons and are in accordance 
with previous reports associating mutations in NEFH 
[4], PRPH [5] or DCTN1 [6] with ALS. PFN1 regulates 
dynamics of actin polymerization but also binds to a 
great variety of proteins serving as a platform involved in 
controlling multiple other cellular processes like mem-
brane trafficking or even splicing events in the nucleus 
[7]. Recently, PFN1 was implicated in the formation 
and clearance of stress granules and seems to harbor an 
intrinsic ability to induce stress granule formation upon 
overexpression [8]. Stress granules are transient cellular 
structures impeding translation upon different stressors 
and are composed of RNA-binding proteins, mRNAs as 
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well as factors involved in translation repression. Chronic 
cellular stress and a pathogenic transition of transient 
stress granules to permanent aggregates of RNA-binding 
proteins are thought to be important in ALS [9].
So far, eight missense mutations in PFN1 have been 
associated with ALS, namely C71G, M114T, E117G, 
G118V [2], T109M [10], R136W [11], A20T and Q139L 
[12]. It has been shown that PFN1 proteins carrying the 
C71G, M114T or G118V substitutions are impaired in 
actin binding while the PFN1 E117G variant retains its 
ability binding to actin [2]. This finding parallels genetic 
evidences supporting monogenic pathogenicity of PFN1 
C71G, M114T and G118V while assigning the PFN1 
E117G variant the role of a risk factor for ALS [2, 12, 
13]. So far, no biochemical data exists about the actin 
binding properties of PFN1 T109M, R136W, A20T and 
Q139L. While the PFN1 R136W, Q139L and A20T muta-
tions were detected in single individuals with sporadic 
or familial ALS, respectively [11, 12], pathogenicity of 
the PFN1 T109M mutation is supported by co-segrega-
tion with the disease in the affected family [10] as well as 
serum microRNA profiles of pre-clinical mutation carri-
ers that are highly similar to profiles of pre-clinical carri-
ers of ALS associated mutations in C9orf72 or SOD1 [14].
In order to further elucidate the relevance of altered 
actin binding for ALS-associated PFN1 mutant proteins, 
we studied in detail the actin binding properties of the 
PFN1 T109M variant as well as its impact on the actin 
cytoskeleton.
Results
Unaltered expression and splicing of PFN1 T109M
The PFN1 c.326C>T mutation causing the T109M sub-
stitution is located directly at an exon/intron boundary 
(first base of Exon 3) [10]. Although not predicted by 
splice site prediction software (e.g. http://www.fruitfly.
org/seq_tools/splice.html), we wanted to rule out the 
possibility that pathogenicity of the PFN1 T109M muta-
tion is due to a haploinsufficiency caused by impaired 
splicing of the mRNA. We therefore measured relative 
PFN1 mRNA abundance and PFN1 protein levels in 
LCLs of five healthy controls as well as in PFN1 T109M 
mutant LCLs of two clinically definite ALS patients and 
three pre-clinical mutation carriers (Fig.  1). No signifi-
cant difference of PFN1 mRNA or PFN1 protein levels 
could be detected between the different groups.
PFN1 T109M is not impaired in ß‑actin binding
The PFN1 T109M substitution is located in close spa-
tial proximity to C71G, M114T, E117G and G118V near 
the actin binding surface of PFN1 [10]. Since PFN1 sub-
stitutions C71G, M114T and G118V but not E117G 
impair actin binding [2] we examined the actin binding 
properties of the PFN1 T109M mutant protein. Addition-
ally, the T109 of PFN1 is a phosphorylation site occupied 
in vivo [15] and altered actin binding by disrupted phos-
phorylation of T109 was suggested before to possibly 
contribute to toxicity of this mutation [10]. We therefore 
performed a co-immunoprecipitation using a V5-anti-
body in lysates of HEK293 cells overexpressing V5-PFN1 
wildtype or different V5-PFN1 mutant proteins including 
a phospho-deficient (T109A) and a phospho-mimicking 
(T109D) mutant. Western blot detection of co-precip-
itated actin revealed no deficits in the binding proper-
ties of PFN1 T109M (Fig. 2a). In contrast to the expected 
opposing effects of the PFN1 T109A and T109D mutant 
proteins on actin binding we found for both an increased 
affinity to actin. Hence, we omitted these artificial phos-
pho-mimicking and phospho-deficient proteins in fur-
ther experiments.
To validate the unchanged actin binding properties 
of PFN1 T109M we performed a pulldown assay using 
recombinant His6-PFN1 (Fig.  2b, c) and quantified the 
PFN1-actin interaction in living cells using a split lucif-
erase complementation assay (Fig. 2d). Both approaches 
confirmed the unchanged actin binding properties of 
PFN1 T109M, while the previously reported reduction 
in actin binding of PFN1 C71G and G118V [2] were 
reproduced.
The actin cytoskeleton of HEK293 cells is not affected 
by PFN1 T109M
Besides binding of actin monomers, another important 
function of PFN1 affecting the polymerization of actin 
is the exchange of actin bound ADP to ATP (see [7] for 
a review). Hence, the unaltered actin binding proper-
ties of the PFN1 T109M mutant protein described above 
do not exclude an impact of this mutation on nucleo-
tide exchange and actin polymerization. To address this 
issue, we stained filamentous actin (F-actin) in HEK293 
cells overexpressing wildtype and mutant V5-PFN1 using 
Phalloidin (Fig.  3). We could not identify any marked 
differences in cell morphology and quantity or distribu-
tion of F-actin between wildtype and mutant V5-PFN1 
expressing cells. Interestingly, even the PFN1 mutants 
C71G (in cells in which this aggregation-prone pro-
tein was not aggregated) and G118V, which are clearly 
impaired in actin binding, still co-localize with the dense 
F-actin structures near the plasma membrane (lamellipo-
dia, filopodia and cortical F-actin).
To further verify the observations of immunocyto-
chemistry, we determined the ratio of filamentous and 
globular actin (F/G-actin ratios) in HEK293 cells over-
expressing wildtype and mutant V5-PFN1 (Fig.  4). Also 
in this experiment no difference was detected between 
cells expressing V5-PFN1 wildtype and C71G (p = 0.502) 
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or T109M mutant protein (p =  0.414). Solely V5-PFN1 
G118V slightly (1.21-fold; p = 0.0471) increased the F/G-
actin ratio compared to wildtype PFN1.
Discussion
In this study, we show that ALS-associated PFN1 T109M 
mutant protein is not impaired in actin binding and does 
not affect the actin cytoskeleton using several different 
approaches. Furthermore, we exclude that pathogenic-
ity of this mutation located directly at an exon/intron 
boundary is due to a splicing defect. Taken together, our 
results provide evidence for additional or alternative 
mechanisms beyond impairment of the actin cytoskel-
eton responsible for motor neuron degeneration associ-
ated with PFN1-linked ALS.
The finding that ALS-associated mutations in PFN1 
are deficient in actin binding suggests disturbed actin 
dynamics to cause motor neuron degeneration [2]. How-
ever, our results show unchanged actin binding of the 
causal PFN1 T109M variant. Therefore, exclusion of 
haploinsufficiency by a splicing defect as the pathogenic 
mechanism of the PFN1 T109M mutation, which is 
located close to an exon/intron boundary [10], is an 
important approach. We were not able to examine CNS 
tissue affected in ALS and thus cannot exclude splicing 
defects in neurons. However, unchanged PFN1 mRNA 
and protein levels in LCLs of ALS patients and pre-clin-
ical carriers of the PFN1 T109M mutation argue against 
haploinsufficiency as the pathogenic mechanism.
Phosphorylation of T109 of PFN1 was proposed to 
fine-tune actin binding and loss of this phosphoryla-
tion site by the T109M substitution might result in dis-
turbed actin dynamics [10]. Increased actin binding of 
the phospho-mimicking PFN1 T109D mutant protein 
reported here would be in line with this hypothesis. 
However, since actin binding of the phospho-deficient 
PFN1 T109A was increased as well and did not show the 
opposite effect of the phospho-mimicking T109D muta-
tion, we conclude that both artificial mutants are not 
suitable to examine the influence of phosphorylation on 
actin binding. Possibly both mutations induce structural 
changes in PFN1 increasing its affinity to actin. Never-
theless, the finding that the phosphorylation-deficient 
PFN1 T109M mutant protein exhibits no differences 
in actin binding compared to wildtype PFN1 (which is 
phosphorylated at T109 [15]) strongly argues for an 
independence of actin binding from the phosphorylation 
of T109 in PFN1.
Further evidence recently provided in yeast supports 
activity of PFN1 T109M mutant protein in actin dynam-
ics. PFN1 T109M and E117G but not C71G, M114T and 
G118V were able to rescue the growth of yeast strains 
depleted in Pfy1, the yeast homolog of PFN1 [8]. Hence, 
the ability to substitute for Pfy1 seems to parallel actin 
binding capability of PFN1. In the same study, a genetic 
screen in yeast identified stress granule formation to be 
closely connected to PFN1 and the recruitment to and 
clearance from stress granules of PFN1 and ALS-asso-
ciated mutant PFN1 proteins as well as their impact on 
stress granule formation was studied in detail using vari-
ous assays. Interestingly, regarding the intrinsic ability 
of PFN1 to induce stress granules upon overexpression 
or the clearance of stress granules from cells after heat 
shock, the PFN1 T109M mutant protein paralleled the 
characteristics of PFN1 C71G, M114T and G118V more 
closely than of PFN1 E117G [8]. Hence, recruitment 
to and clearance from stress granules of PFN1 variants 
seems to be more closely connected to pathogenicity 
than the ability to bind actin. The only exception is the 
recruitment of mutant PFN1 to arsenite-induced stress 
granules. Here, a similar recruitment of PFN1 T109M 
and E117G as well as a decreased recruitment of C71G, 
M114T and G118V indicate an actin dependent mecha-
nism. Further studies are thus warranted to evaluate a 
Fig. 1 PFN1 protein or mRNA levels are not affected by the PFN1 
T109M mutation. a Measurement of relative PFN1 mRNA abundance 
by qRT‑PCR of LCLs of five healthy controls and PFN1 T109M mutant 
LCLs of two ALS patients and three pre‑clinical mutation carriers. 
Results were normalized to U6 snRNA using 2−ΔΔCt‑method (bars 
indicate mean ± SEM). b Western blot comparing amounts of PFN1 
protein of LCLs of five healthy controls, two PFN1 T109M mutant ALS 
patients and three pre‑clinical carriers of the PFN1 T109M mutation. 
Same amounts of protein were pooled in the respective group. Actin 
is shown as a loading control
Page 4 of 8Freischmidt et al. BMC Neurosci  (2015) 16:77 
possible involvement of stress granules in PFN1-linked 
neurodegeneration in more details.
Additional to unchanged actin binding, we show 
that PFN1 T109M has no apparent effect on the actin 
cytoskeleton and does not alter the F/G-actin ratio in 
HEK293 cells. We therefore assume that PFN1 T109M is 
fully functional concerning its interactions with actin, i.e. 
binding and catalysis of nucleotide exchange. However, our 
Fig. 2 PFN1 T109M mutant protein is not impaired in actin binding. a Co‑immunoprecipitation of lysates of HEK293 cells overexpressing wildtype 
and mutant V5‑PFN1 using a V5‑antibody followed by Western blot detection of V5‑PFN1 and actin. b Purified recombinant His6‑tagged wildtype 
and mutant PFN1 (arrowhead) used for the pulldown assay was subjected to SDS‑PAGE followed by staining with coomassie brilliant blue. c His6‑tag 
pulldown using recombinant His6‑PFN1 and lysates of HEK293 cells. His6‑tagged PFN1 and binding proteins were precipitated with Ni–NTA agarose 
(Qiagen) and subjected to Western blotting. d Quantification of the interaction of actin with wildtype and mutant PFN1 using a split luciferase assay. 
Luciferase activity from protein complementation was measured in HEK293 cells 24 h after transfection with plasmids coding for PFN1‑hGluc(1) 
and actin‑hGluc(2). Signals were normalized to the expression of both fusion proteins determined by Western blotting and are shown relative to 
the signal of wildtype PFN1‑hGluc(1) and actin‑hGluc(2) (n = 4; 2–7 measurements each; bars indicate mean ± SEM; *** p ≤ 0.001 in a two tailed 
student’s t test; n.s. = not significant)
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study does not exclude defects of actin dynamics caused by 
PFN1 T109M, e.g. the rate of reorganization of the actin 
cytoskeleton in response to stimuli. Interestingly, overex-
pression of PFN1 C71G and G118V also had no apparent 
effect on the actin cytoskeleton and only PFN1 G118V sig-
nificantly increased the F/G-actin ratio in HEK293 cells. 
These observations are in line with recent results of Boop-
athy and colleagues [16] showing that recombinant PFN1 
C71G, M114T and E117G similarly to wildtype PFN1 
reduce the elongation rate of actin filaments in an in vitro 
polymerization assay. Solely PFN1 G118V showed a trend 
towards impairment of this function. Hence, only PFN1 
G118V seems to have an impact on actin polymerization 
that is different from the wildtype protein.
Taken together, increasing evidence indicates the 
involvement of other/additional mechanisms in PFN1-
linked ALS than impairments of the actin cytoskeleton. 
For example, mutation-induced destabilization of PFN1 
has been suggested [16]. Taking into account the multi-
functionality of PFN1 [7], several additional mechanisms 
are possible. For example, PFN1 interacts directly with 
Fig. 3 Unaltered actin cytoskeleton in HEK293 cells overexpressing wildtype and mutant V5‑PFN1. HEK293 cells transfected with plasmids coding 
for wildtype and mutant V5‑PFN1 were stained for exogeneous PFN1 (anti‑V5) and endogeneous F‑actin (Phalloidin). Note the formation of aggre‑
gates of the V5‑PFN1 C71G protein in roughly 50 % of cells reported previously [2]. Scale bar is 10 µm
Fig. 4 The T109M mutation of PFN1 does not change the F/G‑actin 
ratio in HEK293 cells. Upper panel F/G‑actin ratios of HEK293 cells 
overexpressing wildtype and mutant V5‑PFN1. F‑ and G‑actin frac‑
tions of the respective cell lysates were separated by ultracentrifuga‑
tion and actin levels analyzed by Western blotting and densitometry 
(n = 5; bars indicate mean ± SEM; * p ≤ 0.05 in a two tailed student’s 
t test). Lower panel Representative Western blot of F‑ and G‑actin frac‑
tions used for densitometric analysis
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SMN, a key-player in spinal muscular atrophy (see e.g. 
[17] for a review), and both co-localize in nuclear gems 
[18]. Nuclear gems are sub-nuclear structures involved 
in mRNA splicing events and depletion of nuclear gems 
has been repeatedly reported in ALS (reviewed in [19]). 
Mutant PFN1 could thus influence the regulation of such 
protein/RNA granules. Further studies and analysis of 
additional ALS-associated PFN1 mutant proteins are 
urgently needed to better understand the mechanisms 
ultimately resulting in the death of motor neurons.
Conclusions
This study provides strong evidence that binding of the 
ALS-associated PFN1 T109M mutant protein to actin is 
not impaired and that this mutation has no effect on the 
actin cytoskeleton, suggesting additional or alternative 
mechanisms for PFN1-linked neurodegeneration beyond 
an impairment of cytoskeletal dynamics.
Methods
Patient cohorts and ethics statement
Appropriate approval and procedures were used con-
cerning human subjects. Blood samples were drawn with 
prior informed written consent according to the Declara-
tion of Helsinki (WMA, 1964) approved by the national 
medical ethical review boards. Anonymous genotyping 
by sequencing of the PFN1 gene was performed as previ-
ously described [10].
Analysis of lymphoblastoid cell lines (LCLs)
Epstein-Barr virus transformed LCLs were gener-
ated from healthy controls, PFN1 T109M mutant ALS 
patients as well as pre-clinical mutation carriers.
cDNA of LCLs was used for quantitative real-time 
PCR (qRT-PCR) measurements of PFN1 mRNA run on 
a CFX96 Real-Time System (Bio-Rad) using oligonucleo-
tides spanning Exons 2 and 3: 5′-GCCAGAAATGTTCGG 
TGATC-3′ and 5′-CTTTGCCCATCAGCAGGAC-3′. 
Results were normalized relative to U6 snRNA [20] using 
2−ΔΔCt-method [21].
Lysates of LCLs were subjected to Western blotting 
using rabbit anti-ß-actin (Cell Signaling Technology Cat# 
4970 RRID:AB_2223172) and rabbit anti-PFN1 (Sigma-
Aldrich Cat# P7749 RRID:AB_1079599) antibodies. 
Secondary antibody was goat anti-rabbit IgG-HRP (Life 
Technologies Cat# G21234 RRID:AB_10837906).
Plasmids
Eukaryotic expression vector of human N-termi-
nally V5-tagged PFN1 [GenBank:NM_005022.3] was 
pcDNA3.1/nV5-DEST (Invitrogen) previously described 
[2]. PFN1 T109M, T109A and T109D mutations were 
introduced using site directed mutagenesis (Table 1).
Expression vectors for the split luciferase comple-
mentation assay were pcDNA3.1-Zipper-hGluc(1) 
and pcDNA3.1-Zipper-hGluc(2) [22] previously used 
for detection of α-synuclein oligomers [23]. The cod-
ing sequence of α-synuclein was replaced by the coding 
sequence of human ß-actin [GenBank:NM_001101.3] or 
PFN1 (wt or mutants), resulting in expression constructs 
coding for PFN1-hGluc(1) and actin-hGluc(2).
For expression of N-terminally His6-tagged recom-
binant PFN1 in E. coli we used pRSET B vector (life 
technologies).
Cultivation and transfection of HEK293 cells
HEK293 cells were cultivated in DMEM  +  10  % FCS 
(Gibco). Transfections were carried out using the cal-
cium-phosphate method as described before [24] with 
minor modifications.
Co‑immunoprecipitation
Co-immunoprecipitation of ß-actin with V5-PFN1 
in lysates of HEK293 cells was performed as previ-
ously described [2]. For Western blot detection of 
V5-PFN1 and ß-actin we used mouse anti-V5 (Life 
Technologies Cat# R96025 RRID:AB_10050879) and 
rabbit anti-ß-actin (Cell Signaling Technology Cat# 
4970 RRID:AB_2223172) antibodies. Secondary anti-
bodies were goat anti-mouse IgG-HRP (Life Tech-
nologies Cat# G21040 RRID:AB_11180340) and goat 
anti-rabbit IgG-HRP (Life Technologies Cat# G21234 
RRID:AB_10837906), respectively.
Split luciferase complementation assay
Luciferase activity from protein complementation was 
measured in HEK293 cells co-transfected with PFN1-
hGluc(1) and actin-hGluc(2) 24  h post-transfection as 
previously described [23] using Multilabel Reader Victor 
Table 1 Oligonucleotides used for  generation of  PFN1 
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X3 (Perkin Elmer). Luciferase signal was normalized to 
expression of PFN1-hGluc(1) and actin-hGluc(2) deter-
mined by Western blotting.
Expression and purification of His6‑PFN1 in E. coli
His6-tagged PFN1 was expressed for 4  h upon IPTG-
induction (1  mM) at 37° C in E. coli BL21(DE3)pLysS 
(Novagen). Purification of recombinant PFN1 was per-
formed under native conditions in a batch mode using Ni–
NTA agarose (Qiagen) as specified by the manufacturer.
His6‑PFN1 pulldown
HEK293 lysates in RIPA buffer were incubated for 1 h with 
His6-PFN1 at 4 °C with constant rotation. Ni–NTA agarose 
(Qiagen) equilibrated in RIPA buffer was added and further 
incubated for 1  h. Subsequently, the beads were washed 
four times with RIPA buffer + 10 mM imidazole and finally 
boiled in protein sample buffer  + 200 mM imidazole. 
Western blot detection of His6-PFN1 and ß-actin was per-
formed with antibodies already used for LCL analysis.
Immunocytochemistry
24  h post-transfection, HEK293 cells overexpressing 
wildtype and mutant V5-PFN1 were washed in PBS, fixed 
for 10 min in Roti-Histofix 4 % (Roth), permeabilized for 
10 min in PBS supplemented with 0.1 % Triton X-100 and 
100 mM glycine and blocked for 45 min in PBS with 1.5 % 
bovine serum albumin and 0.1  % Tween20. Afterwards, 
cells were incubated for 1  h with the primary antibody 
mouse anti-V5 (see above; 1:750 in PBS), washed in PBS 
and incubated for 1  h with the secondary antibody goat 
anti-mouse DyLight 488 (Thermo Fisher Scientific Cat# 
35502 RRID:AB_844397; 1:500 in PBS) and Phalloidin-
Atto 594 (Sigma-Aldrich Cat# 51927; 600  nM in PBS) 
followed by washing in PBS. Cell nuclei were stained for 
10 min using DAPI (1 µg/ml in PBS). After a final washing 
in PBS, cells were mounted on microscope slides and ana-
lyzed using a Carl Zeiss Axio Observer.A1 microscope.
Filamentous/globular (F/G) actin assay in HEK293 cells
24  h post-transfection, HEK293 cells overexpressing 
wildtype and mutant V5-PFN1 were washed in PBS 
and lysed at room temperature in F-actin stabiliza-
tion buffer [50 mM PIPES, pH 6.9, 50 mM NaCl, 5 mM 
MgCl2, 5  mM EGTA, 5  % glycerol, 0.1  % NP-40, 0.1  % 
Triton X-100, 0.1 % Tween20, 0.1 % β-mercaptoethanol, 
1  mM ATP, complete protease inhibitor (Roche)]. After 
adjustment to a total protein concentration of 2 mg/ml, 
lysates were centrifuged at 100,000×g and 25° C for 1 h 
and supernatants were transferred to a new tube repre-
senting the G-actin fraction. The pellets (F-actin fraction) 
were completely dissolved in the initial volume of solubi-
lization buffer [10 mM Tris, pH 8.0, 150 mM NaCl, 2 % 
SDS, complete protease inhibitor (Roche)] by three sub-
sequent cycles of sonication, heating to 70 °C for 10 min 
and cooling down to room temperature. Equal volumes 
of the F- and G-actin fractions were subjected to Western 
blotting followed by detection of ß-actin using antibodies 
described above. Western blots were densitometrically 
analyzed using ImageJ software.
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